Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 12,057 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Diseases Clear all
Completed No phase listed Observational

Patient Outcomes Evaluation of the EBI Vuelock™ Anterior Cervical Plate System

NCT00726128
View directory record Official record
Conditions
Trauma, Tumor, Pseudarthrosis, Scoliosis, Degenerative Disc Disease
Interventions
VueLock™ Anterior Cervical Plate
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
Not listed
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
4
States / cities
Palo Alto, California • San Diego, California • Avon, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention

NCT02970136
View directory record Official record
Conditions
Human Papillomavirus, Human Immunodeficiency Virus, Hepatitis C, ColoRectal Cancer
Interventions
OraQuick Swab, Fecal Immunochemical Test, OraQuick Fingerstick, Standard Screening Tests, HPV Self-Sampling Test, Home Based Screening Tests
Device · Other
Lead sponsor
University of Miami
Other
Eligibility
50 Years to 64 Years
Enrollment
754 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

NCT00958971
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 21, 2026, 5:28 PM EDT
Terminated Not applicable Interventional Results available

The Pristine Post-Market Study

NCT05228132
View directory record Official record
Conditions
Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure, Central Venous Catheter Related Bloodstream Infection, End Stage Renal Disease
Interventions
Pristine™ Long-Term Hemodialysis Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
6
States / cities
Dothan, Alabama • New Haven, Connecticut • Shreveport, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Jul 21, 2026, 5:28 PM EDT
Terminated Phase 1 Interventional

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

NCT03420963
View directory record Official record
Conditions
Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Male Reproductive System Neoplasm, Recurrent Malignant Mesothelioma, Recurrent Malignant Neoplasm of Multiple Primary Sites, Recurrent Malignant Oral Neoplasm, Recurrent Malignant Pharyngeal Neoplasm, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Soft Tissue Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Thyroid Gland Neoplasm, Recurrent Malignant Urinary System Neoplasm, Refractory Cutaneous Melanoma, Refractory Malignant Bone Neoplasm, Refractory Malignant Endocrine Neoplasm, Refractory Malignant Female Reproductive System Neoplasm, Refractory Malignant Male Reproductive System Neoplasm, Refractory Malignant Mesothelioma, Refractory Malignant Neoplasm of Multiple Primary Sites, Refractory Malignant Oral Neoplasm, Refractory Malignant Pharyngeal Neoplasm, Refractory Malignant Skin Neoplasm, Refractory Malignant Soft Tissue Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Malignant Thyroid Gland Neoplasm, Refractory Malignant Urinary System Neoplasm
Interventions
Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, Etoposide
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Months to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 5:28 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Multi-Omics for Maternal Health After Preeclampsia

NCT06340152
View directory record Official record
Conditions
Pre-Eclampsia, Pregnancy Induced Hypertension
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 21, 2026, 5:28 PM EDT
Recruiting Phase 1 Interventional

A Study of AZD0120 in Autoimmune Diseases

NCT07295847
View directory record Official record
Conditions
Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions
AZD0120
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Tucson, Arizona • Stanford, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 21, 2026, 5:28 PM EDT
Recruiting No phase listed Observational

A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)

NCT05813678
View directory record Official record
Conditions
Phenylketonuria (PKU)
Interventions
Pegvaliase
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
12
States / cities
Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Natural Killer Cells and Bortezomib to Treat Cancer

NCT00720785
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
Interventions
Bortezomib, NK cells
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 3 Interventional

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

NCT00938652
View directory record Official record
Conditions
Breast Cancer
Interventions
gemcitabine/carboplatin, Iniparib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
102
States / cities
Birmingham, Alabama • Sedona, Arizona • Jonesboro, Arkansas + 98 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Jul 21, 2026, 5:28 PM EDT
Withdrawn Phase 2 Interventional

Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma

NCT02628704
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Placebo (for selinexor), carfilzomib, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
West Hollywood, California • Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

NCT03294538
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Jul 21, 2026, 5:28 PM EDT
Not listed Phase 2Phase 3 Interventional

MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant

NCT00283738
View directory record Official record
Conditions
Migraine, Aura, Patent Foramen Ovale
Interventions
BioSTAR Septal Repair Implant System, Sham Procedure
Device · Procedure
Lead sponsor
NMT Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Stamford, Connecticut • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2008 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

A Clinical Trial of KT07 Capsule in the U.S.A

NCT02867358
View directory record Official record
Conditions
Influenza, Human
Interventions
KT07 Capsule, Placebo
Drug · Other
Lead sponsor
Yiling Pharmaceutical Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
81
States / cities
Birmingham, Alabama • Pelham, Alabama • Tolleson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Jul 21, 2026, 5:28 PM EDT
Suspended Not applicable Interventional

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

NCT01305148
View directory record Official record
Conditions
Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions
Warfarin GenoSTAT Test
Device
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion

NCT02338648
View directory record Official record
Conditions
Chalazion
Interventions
SUN-131 1.5% TDS, Placebo TDS
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Santa Ana, California • Littleton, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis

NCT02638948
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986142, Placebo, Methotrexate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 120 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Huntsville, Alabama • Fullerton, California • Hemet, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Not applicable Interventional Results available

Dried Blood Spot Testing of CMV Detection in HCT Recipients

NCT03910478
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
DBS Self-Collection Kit, Standard Control Strategy
Device · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years to 99 Years
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Minneapolis, Minnesota • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 21, 2026, 5:28 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acoustic Waveform Respiratory Evaluation

NCT06512064
View directory record Official record
Conditions
Asthma, COPD, Cystic Fibrosis, Ciliary Motility Disorders, Bronchiectasis, Airway Malacia, Healthy Control
Interventions
AWARE
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
8 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 21, 2026, 5:28 PM EDT
Completed No phase listed Observational

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

NCT04014764
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm
Interventions
This is a non-interventional study
Other
Lead sponsor
Notable Labs
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Bakersfield, California • San Luis Obispo, California • Grand Junction, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Jul 21, 2026, 5:28 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings

NCT03619798
View directory record Official record
Conditions
Diagnoses Disease
Interventions
HemoTypeSC
Device
Lead sponsor
Silver Lake Research Corporation
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Jul 21, 2026, 5:28 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

NCT03870763
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Dimethyl Fumarate, Peginterferon Beta-1a, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 21, 2026, 5:28 PM EDT
Completed No phase listed Observational

Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated

NCT01281293
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
7 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
7
States / cities
Atlanta, Georgia • Peoria, Illinois • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Jul 21, 2026, 5:28 PM EDT
Suspended Phase 1 Interventional

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

NCT03710421
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
CS1-CAR T Therapy, Cyclophosphamide, Fludarabine, Leukapheresis
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 21, 2026, 5:28 PM EDT